is a pioneer in the field examining how disruptions in intrinsically disordered segments in proteins perturb phase transitions and underlie neurological diseases, such as ALS. In an interview with Neuron, he shares how understanding first principles of biology is essential for disease therapy development, why ''fishing expeditions'' are his favorite experiments, and how he overcame NIH budget cuts when starting his lab.
J. Paul Taylor is an investigator of the Howard Hughes Medical Institute and chair of the Department of Cell and Molecular Biology at St. Jude Children's Research Hospital. He received his MD and PhD from Jefferson Medical College in Philadelphia, after which he pursued clinical training in neurology at the University of Pennsylvania. He completed a neurogenetics fellowship under the mentorship of Kenneth Fischbeck at NIH, where he cultivated an interest in the molecular underpinnings of neurodegenerative disease. His current research program originated from the discovery that mutations that cause ALS and related diseases tend to impact intrinsically disordered segments in proteins-so-called lowcomplexity sequence domains (LCDs). This finding led to the discovery that LCDs support the phenomenon of biological phase transitions and that perturbed phase transitions underlie certain neurological diseases. His lab is pursuing three broad goals derived from these fundamental observations: first, to understand the mechanism of LCD-mediated phase transitions; second, to define the larger role of phase transitions as a major organizing principle in the cell; and, third, to determine precisely how disturbances of phase transitions cause disease.
What do you think are the big questions to be answered next in your field? There are at least two big questions that I find pressing in my field. The first question is how extensive and pervasive phase transitions are in cell biology and precisely how biological processes are controlled by these phase transitions. We have been astonished to suddenly appreciate that cellular features we have recognized for a long time (e.g., assembly of nucleoli, nuclear speckles, and RNA granules) and likely other types of dynamic assemblies (e.g., superenhancers, DNA repair machinery, mitotic spindles, clustered membrane receptors) are governed by the principles of phase transitions. It's evident from the outset that cooperativity arising from multivalent low-affinity interactions are governing this process and that one of the principal contributors is low-complexity sequences. Beyond these simple principles, however, the role of phase transitions in biology are almost entirely unexplored. For example, we don't know how information is encoded to allow the right molecules to come together in the right place at the right time, and we don't know how many different aspects of biology are controlled by this process. The second big question to answer is how phase transitions are disrupted by disease mutations in low-complexity sequences and whether disturbances in phase transitions are a significant contributor to neurological disease. And if that's true, we need to define precisely what those disturbances are.
Amazingly, the presence of liquid-like organelles and the fact that a cell could be viewed as an entity with material properties with distinct phases were recognized by E.B. Wilson in 1899. This observation was a lost memory for long time but was uncovered and reinvigorated by observations by Cliff Brangwynne and Tony Hyman in 2009. Only in recent years did the molecular underpinnings of this process begin to emerge. It's an old, but new, exciting field.
To tackle your favorite research question, is there a tool that either needs to be developed or is currently available that could be implemented in a novel way? An incredibly useful technology that comes immediately to mind would be the ability to perform proteomics on a single-cell scale. This seems far-fetched, but plenty of recent advances that seemed absurd 10 years ago have come online. Super-resolution microscopy comes to mind as an example; we all believed that there was a refraction limit that couldn't be overcome, but some brilliant engineering circumvented that problem.
The Cell Symposium that you are speaking at this year covers talks from cell biology to cognition and from animal models to human neuroscience. How do you view the level of crosstalk between these disciplines and how can they profit/ learn from each other? I think that the level of crosstalk is quite good, although it can always be better.
Perhaps some investigators burrow into one area and don't look around, but there are many individuals successfully straddling these disciplines and still many more that work collaboratively. I think the bigger issue is the integration of structural biology/biophysics and neurobiology-that's a divide that is more challenging and deserves more attention, because there's very limited appreciation of the importance of biophysics in neurobiology. Right now, these two disciplines are largely unaware of each other.
Do you have a favorite anecdote from doing science that you'd like to share (perhaps a key discovery moment)? Early on, my lab focused on the identification of genetic modifiers of ALS and related diseases by screening in Drosophila. At the same time, in my neurology clinic, I began collecting DNA samples from patients with weird conditions. I don't know what I was expecting to do with these samples when I collected them, since the families of these patients were too small to give any hope of finding the causative genes using approaches available at that time. Years later, I moved to St. Jude Children's Research Hospital, where they established the Pediatric Cancer Genome Project. I was fortunate to piggyback on this effort and gain access to next-generation sequencing of my DNA samples at a very early stage in the technology. In the first family I sequenced, we identified the causative mutation in HNRNPA2B1, a gene we had already published as a genetic modifier of ALS. In the second family, we identified the identical causative mutation in HNRNPA1-a gene we had also published as a genetic modifier of ALS. In both genes, the missense mutations impacted the LCD, which we subsequently discovered underlies the phase transition that builds membrane-less organelles. It was extremely gratifying to see validation of Drosophila as a tool that can predict the genetic underpinnings of human neurodegenerative disease. Moreover, the discoveries that came from combining this genetic model and human studies are driving my research program to this day.
Who were your key early influences? Kurt Fischbeck, my mentor during my fellowship years at the NIH, has been very influential for me. I try to emulate his deep critical thinking and his very collegial and decent approach to scientific citizenry. I've also really admired the team of Huda Zoghbi and Harry Orr. They were iconoclasts in the field of polyglutamine repeat diseases, which is the field I studied as a postdoc. At that time, Huda and Harry relentlessly pursued a line of investigation that was really distinct from the common thinking at the time. They focused on the normal function of disease genes rather than following the crowd, most of whom subscribed to the idea that disease was driven exclusively by protein aggregation.
What's your favorite experiment? As I've matured as a scientist and gone through more cycles of success and failure, I've found that my favorite class of experiment is a well-designed, hypothesis-generating screen. I'm less and less inclined to design hypothesis-testing experiments at the outset of a project. In hypothesis-testing experiments, I think it's difficult for the designer to fully appreciate the extent of their unintended, subconscious bias in both the design and subsequent interpretation of their experiments. There is certainly a place for these types of experiments, but I believe it's best to delay the hypothesis-testing experiments for as long as possible in the process. With my group, I am like a broken record about unbiased, inductive, hypothesisgenerating approaches that can yield unanticipated insights. Regrettably, this type of experiment is often disparaged by study sections as ''fishing expeditions,'' but if one perseveres, something illuminating-and often important insights-will emerge from a well-designed unbiased screen.
What is your view on big datagathering collaborations as opposed to hypothesis-driven research by small groups? I'm sure that big data-gathering collaborations include some worthy projects and some less worthy projects. But there are some very worthy projects in neurodegeneration. It's clear that there is an enormous genetic contribution to ALS, but so far we've only scratched the surface of this by focusing on the highly penetrant disease alleles that cause the more common forms of familial ALS. For the vast majority of patients who have sporadic ALS, in which there is obviously a genetic component, we don't know what that genetic risk is. The only way to find those genetic determinants is to collect, genotype, and sequence vast numbers of patients from various ethnicities and collectively analyze that data. It's basically a hypothesis-generating approach on a grand scale. I believe that these types of projects represent the next essential step in understanding the molecular basis of ALS and related diseases.
What do you think are the biggest problems/challenge science as a whole is facing today? My greatest concern is a loss of confidence and appreciation among the United States public for the role that basic science plays in society. This manifests in diminishing interest in investing in science and diminishing interest in appreciating the outcome of science. In my observation, there is greater public buy-in to the societal benefits of science in Europe and Asia, and I don't know why that is.
What is your view on the role of science/neuroscience for society? I think it's important for two main reasons. On the one hand, looking inward, understanding who we are and how we work is important for appreciating and understanding the complexity of human life. On the other hand, more practically speaking, we can sit idly by as patients get sick and die, or we can try to improve their options for therapy. The only way to improve those options is to build upward: begin by developing an understanding of first principles, move up to disease systems, and then develop translational work.
Which aspect of science-your field or in general-would you wish the general public knew more about? I wish the general public had a greater appreciation for the role of basic science in providing the essential foundation for any kind of translational science. There are innumerable examples, but here I would hold up the recent therapeutic breakthrough for spinal muscular atrophy as a recent and highly relevant success story. Restoration of normal splicing of the SMN2 gene with antisense oligonucleotides represents the first effective, FDA-approved therapy for a neurodegenerative disease. Developing this therapy required identification of the SMN1 and SMN2 genes, learning how the SMN genes function, a detailed knowledge of their splicing (to say nothing of the fundamental understanding of RNA splicing itself), and much more. In parallel, we also needed to learn how to create oligonucleotide RNAs that are stable, are non-toxic, and can reach their targets in humans. Much of this work is not glamorous and seems far removed from the clinic but is absolutely essential.
In your opinion, what are the most pressing questions for the field?
We are entering a new era where therapies that are rationally developed in the lab are reaching patients for the first time. This stage is most notable for muscular dystrophy and spinal muscular atrophy, but disease-altering interventions for a host of degenerative diseases (e.g., ALS, Parkinson's disease, spinocerebellar ataxia, Alzheimer's disease, frontotemporal dementia) may be just around the corner. With these therapies coming into the clinic now, we have to contend with a crucial question: to what extent is degeneration reversible? There have been experiments performed in mice, in which researchers tried to replicate disease and then reverse it, and in some cases the results have been very promising. But everyone is holding their breath now to find out what will happen in people who undergo treatment for each of these diseases. Is our best hope to arrest the disease in its tracks and avoid further decline? Or is it possible to restore function? Nobody knows.
Where do you see the strongest potential for progress and new breakthroughs in neuroscience? I think it's in understanding the role of phase transitions in governing neuronal biology. Phase transitions are particularly important for neurons because this process seems to be intimately tied to the appropriate spatial distribution of biomolecules-and RNA in particular. Neurons are obviously architecturally complex and cover a vast amount of space, and biomolecules need to get to specific places to carry out their functions. One-half of this equation is obviously motor-based transport. But there are also unappreciated relationships between phase transitions and transport.
How do you find inspiration? I find inspiration from dialog with my colleagues. Every week I bring my trainees into my office in different mixed and matched combinations, where we just sit and have a conversation about data and what they might mean. I find it fruitless to sit and think on my own-I've never had a brilliant idea that way. It always emerges from a discussion.
Do you have a role model in science? If so, who and why?
There are different qualities that I draw from a wide variety of people that I've encountered over my career, but in composite, they are probably best captured by Mike Brown and Joe Goldstein. They followed the full arc from taking insights from patients into the lab to perform fundamental studies that became increasingly translational and ultimately reached back to the clinic and dramatically improved the lives of millions of people.
What do you do when you're not in the lab? My life outside the lab used to be really about my kids-for much of my career, my activities would revolve around their activities. They're now teenagers, and I've had to find something else to occupy my time. For some years, I caught up on reading, but lately I'm enjoying playing guitar, which I started about 6 years ago and now play every day.
Did you encounter particular difficulties? How did you overcome them? When I first started my lab at the University of Pennsylvania in 2004, I had very limited resources. I was in a financial hole almost right out of the gate. To maintain my lab, I needed to get an R01 within about the first 18 months. So I submitted an R01 relating to spinal bulbar muscular atrophy (SBMA, or Kennedy's Disease), and it scored below the established payline at the time. But then the payline suddenly dropped and the grant wasn't funded (this was before the early-stage investigator policy). I was staring failure in the face. Soon after, I got a call from the vice dean saying that he had heard about my grant, and he wanted to know whether I would be willing to discuss it with a reporter from the Philadelphia Inquirer. The reporter was writing an article about the federal budget and how pay cuts at the NIH coincided with the start of the Iraq war. I agreed to the interview and ended up being the lead narrative of the article, which painted a picture of a lab that was imminently going to close. After the article was picked up nationally, I got a phone call from the Kennedy's Disease Association. They had raised $50,000 for me to keep my lab open. I used those funds to pay my postdoc Udai Pandey, who several years later became first author on my lab's first Nature paper.
What advice do you find yourself giving to your students and postdocs? My advice basically relates to investing substantial thought upfront to guide the choice of a meaningful, but also tractable, scientific question. Nature gives up its secrets in mysterious ways, and sometimes the timing is just not right to discover something in an otherwise important field. Progress is not always steady, and fields of investigation can stagnate. This may happen because the field is waiting for the next technological advance or illuminating insight to reinvigorate that field and get them over the stagnant period. Next, once meaningful and tractable question is defined, pursue the approaches that are most appropriate to answer that question regardless of whether you know how to do them. Learn new things and ask for help.
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